These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Developments in the pharmacotherapy of the overactive bladder. Sellers DJ; McKay N Curr Opin Urol; 2007 Jul; 17(4):223-30. PubMed ID: 17558263 [TBL] [Abstract][Full Text] [Related]
4. Improving the global management of the neurogenic bladder patient: part I. The complexity of patients. Denys P; Corcos J; Everaert K; Chartier-Kastler E; Fowler C; Kalsi V; Nitti V; Schulte-Baukloh H; Schurch B Curr Med Res Opin; 2006 Feb; 22(2):359-65. PubMed ID: 16466608 [TBL] [Abstract][Full Text] [Related]
5. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424 [TBL] [Abstract][Full Text] [Related]
6. [Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients]. de Sèze M; Ruffion A; Haab F; Chartier-Kastler E; Denys P; Game X; Karsenty G; Kerdraon J; Perrouin-Verbe B; Saussine C; Soler JM; Amarenco G Ann Readapt Med Phys; 2008 May; 51(4):315-21. PubMed ID: 18514963 [TBL] [Abstract][Full Text] [Related]
7. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Mascarenhas F; Cocuzza M; Gomes CM; Leão N Neurourol Urodyn; 2008; 27(4):311-4. PubMed ID: 17914742 [TBL] [Abstract][Full Text] [Related]
9. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831 [TBL] [Abstract][Full Text] [Related]
10. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396 [TBL] [Abstract][Full Text] [Related]
11. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application. Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971 [TBL] [Abstract][Full Text] [Related]
12. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? Ruffion A; Capelle O; Paparel P; Leriche B; Leriche A; Grise P BJU Int; 2006 May; 97(5):1030-4. PubMed ID: 16643486 [TBL] [Abstract][Full Text] [Related]
13. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction. Pannek J; Göcking K; Bersch U BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Kennelly MJ; Lemack GE; Foote JE; Trop CS Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264 [TBL] [Abstract][Full Text] [Related]
15. The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. Sahai A; Khan MS; Arya M; John J; Singh R; Patel HR Expert Opin Pharmacother; 2006 Apr; 7(5):529-38. PubMed ID: 16553568 [TBL] [Abstract][Full Text] [Related]
16. Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Kajbafzadeh AM; Moosavi S; Tajik P; Arshadi H; Payabvash S; Salmasi AH; Akbari HR; Nejat F Urology; 2006 Nov; 68(5):1091-6; discussion 1096-7. PubMed ID: 17113899 [TBL] [Abstract][Full Text] [Related]
17. Treatment of neurogenic incontinence with botulinum toxin A. Schurch B; Schmid DM; Stöhrer M N Engl J Med; 2000 Mar; 342(9):665. PubMed ID: 10702067 [No Abstract] [Full Text] [Related]
18. Management of overactive bladder and urge urinary incontinence in the elderly patient. Erdem N; Chu FM Am J Med; 2006 Mar; 119(3 Suppl 1):29-36. PubMed ID: 16483866 [TBL] [Abstract][Full Text] [Related]